Stock footage of Novavax as Covid-19 jab shows 89% eficacy

Mandatory courtesy: Novavax Stock footage from Novavax's laboratory following the US company announcing that their Covid-19 jab has shown to be 89.3% effective at preventing coronavirus in participants in its Phase 3 clinical trial in the UK, which involved more than 15,000 people aged between 18-84, of which 27% were older than 65, Novavax said.